THBD and neoplasm: The percentages of DCs in tumor did not seem to vary in NSCLC patients with different disease stages, except possibly for CD141+ DCs which were more frequent in stage I compared to stage II NSCLC, although the p-value was borderline significant (p = 0.04) and will need to be confirmed with a larger patient cohort (Supplementary Figure 12).